Propositive follow-up: Long-term immune responses to the 4CMenB and MenACWY vaccines in people living with HIV.
Alberto San Francisco RamosCatherine IsittShehnaz AthaideShamez N LadhaniNicholas J AndrewsKelly Townsend-PayneAnn HollandJennifer LouthRay BorrowPaul T HeathCatherine A CosgrovePublished in: HIV medicine (2023)
Immune responses against MenB in our cohort of people living with HIV at 2.5 years of follow-up were reassuring, with 68.8% of participants retaining protection against all three reference strains. However, responses against MenC were lower than those against MenA, W, and Y serogroups.